Conference Schedule, as of October 24, 2020
At the conference you will receive our Daily Update Bulletin with any changes.

Friday, October 23, 2020
• Registration is open, go to www.thyca.org/conference
• All program times are EDT
• Visit the Exhibit Hall
• Check out our online auction, www.thyca.org/auction
• Your feedback is important! Please fill out your evaluation forms

10:00 – 11:10 a.m. EDT
101 Roundtable: If you’re new to thyroid cancer – things to know and questions to ask. Barb Allhoff, ThyCa Volunteer. Room 1 [N]
102 Roundtable: If this is your first conference – things to know and questions to ask. Joel Amromin, ThyCa Volunteer. Room 2
103 Get “Schooled”: Educational accommodations and advocacy for children diagnosed with thyroid cancer. Pam Mendenhall, LISW. ThyCa Pediatric Support Moderator. Room 3

11:30 – 11:40 a.m. EDT
111 Welcome and announcements. Howard Solomon, ThyCa Volunteer. Room 1

11:45 a.m. – 12:45 p.m. EDT Getting to know each other. Open microphone roundtables.
121 If the first letter of your last name starts with A through D. ThyCa Volunteers. Room 1
122 If the first letter of your last name starts with E through K. ThyCa Volunteers. Room 2
123 If the first letter of your last name starts with L through Q. ThyCa Volunteers. Room 3
124 If the first letter of your last name starts with R through Z. ThyCa Volunteers. Room 4

1:15 – 2:15 p.m. EDT
131 The ABCs of thyroid cancer: Understanding key terms, concepts, and initial diagnostic and treatment steps. Kaniksha Desai, MD, ECNU, Endocrinologist. Room 1
132 Thyroid surgery. (1) When is active surveillance the right decision? Reconciling divergent opinions on treatment. (2) Surgical complications after thyroidectomy, including voice issues and hypoparathyroidism. Allen S. Ho, MD, Surgeon. Room 2
133 Medullary thyroid cancer roundtable: Getting to know each other – MTC survivors and caregivers. Bill McClain and Kathryn Wall, ThyCa Volunteers. Room 3 [C, M]
134 Lifestyle and cancer: Managing stress and anxiety. Scott A. Irwin, MD, PhD, Psychiatrist. Room 4
135 Updates on the management of anaplastic thyroid cancer. Maria E. Cabanillas, MD, Oncologic Endocrinologist. Room 5 [A]

Session Key by Suggested Audience
You are welcome to attend any session. The key indicates sessions of interest to a particular audience.
Friday, October 23, 2:45 – 3:45 p.m. EDT
141 Panel discussion: About thyroid hormone therapy, testing, and dosing including T4, T3, and desiccated thyroid. Can my thyroid hormone preparation and dosing affect how I feel?
   Room 1 [A,ADV,M,PF]
   - Thyroxine replacement preparation, testing, targets and monitoring topic, and the new consensus statement on T4/T3 preparations. Gregory Brent, MD, Endocrinologist, and Jerome M. Hershman, MD, Endocrinologist.
   - Understanding thyroid hormone metabolism. Jonathan S. LoPresti, MD, PhD, Endocrinologist
142 Novel chemotherapies for patients with metastatic papillary, follicular, or Hurthle cell thyroid cancer. Maria E. Cabanillas, MD, Oncologic Endocrinologist. Room 2 [Adv]
143 Medullary thyroid cancer: Medical management at the beginning of the journey. Naifa L. Busaidy, MD, Endocrinologist, and Elizabeth G. Grubbs, MD, Surgeon. Room 3 [M]
144 Panel discussion: Lifestyle and cancer. Room 4
   - Diet, and healthy eating. Stephen J. Freedland, MD, Integrative Medicine.

4:15 – 5:15 p.m. EDT
151 Panel discussion: Managing thyroid nodules: Determining if they are malignant or benign, and potential surgical planning. Room 1 [A,ADV,M,PF]
   - Molecular testing of indeterminate thyroid nodules. Erik K. Alexander, MD, Endocrinologist.
   - Ultrasound imaging for lymph-node mapping and fine needle aspiration for surgical planning in thyroid cancer. Julia E. Noel, MD, Head & Neck Surgeon.
152 Panel discussion: Diagnosis and management of thyroid cancer in pregnancy. Moderator: Peter A. Singer, MD, Endocrinologist, Contributor: Aime T. Franco, PhD, Survivor. Room 2 [PF]
   - Evaluating thyroid nodules found during pregnancy, and managing thyroid cancer found during pregnancy. Trevor E. Angell, MD, Endocrinologist.
   - What to do about metastatic thyroid cancer during pregnancy
   - What if thyroid cancer surgery is needed during pregnancy. Daniel Kwon, MD, FACS, Head & Neck Surgeon.
153 When should one consider tyrosine kinase inhibitor therapy for medullary thyroid cancer? Robert F. Gagel, MD, Endocrinologist, and Mark E. Zafereo, MD, Head and Neck Surgeon. Room 3 [M]
154 Pediatric Thyroid Cancer Roundtable: Coping, Treatment Options, and Being Part of a Community of Survivors. Carol DiFelice, and Pam Mendenhall, LISW, ThyCa Volunteers. Room 4 [Ped]
155 Roundtable on health promotion: Sharing experiences with diet, exercise, and other complementary approaches to well-being. Cal Pierce, ThyCa Volunteer. Room 5 [M]

Session Key by Suggested Audience
You are welcome to attend any session. The key indicates sessions of interest to a particular audience.
A: Anaplastic   Adv: Advanced Disease   AYA: Adolescent/Young Adult   C: Caregivers   Esp: Spanish
M: Medullary   N: Newly Diagnosed   Ped: Pediatric   PF: Papillary/Follicular
Friday, October 23, 5:45 – 6:45 p.m. EDT
161 Roundtable: Percutaneous Alcohol Ablation for Treatment of Thyroid Cancer Nodules. Daria Jerauld, ThyCa Volunteer. Room 1
162 Roundtable: "How do you meditate anyway?” Roberta Perry, ThyCa Volunteer. Room 2
163 Roundtable: You’re new to thyroid cancer and you want to talk about your journey. Roselle Kovitz, ThyCa Volunteer. Room 3
164 Roundtable: Craft and Connect. Alexa Jett, ThyCa Volunteer. Room 4
165 AYA Roundtable: Let’s talk about keeping a job while dealing with thyroid cancer. Samantha Weese, ThyCa Volunteer. Room 5 [AYA]

7:00 – 8:00 p.m. EDT
171 Young adults virtual meet-up. For people ages 18 – 40. Samantha Weese, ThyCa Volunteer. Room 1 [AYA]
172 Virtual anaplastic thyroid cancer meet-up. Patti Turner, ThyCa Volunteer. Room 2 [A]
173 “Meddie” (medullary thyroid cancer) virtual meet-up. Bill McClain, ThyCa Volunteer. Room 3 [M]

Session Key by Suggested Audience
You are welcome to attend any session. The key indicates sessions of interest to a particular audience.
A: Anaplastic  Adv: Advanced Disease  AYA: Adolescent/Young Adult  C: Caregivers  Esp: Spanish
M: Medullary  N: Newly Diagnosed  Ped: Pediatric  PF: Papillary/Follicular
Saturday, October 24, 2020

- Registration is open, go to [www.thyca.org/conference](http://www.thyca.org/conference)
- All program times are EDT
- Visit the Exhibit hall
- Check out our online auction, [www.thyca.org/auction](http://www.thyca.org/auction)
- Your feedback is important! Please fill out your evaluation forms

10:00 – 11:10 a.m. EDT

211 Genetic testing for inherited syndromes in newly diagnosed non-medullary thyroid cancer in young patients including PTEN and DICER1 related syndromes. Yuri E. Nikiforov, MD, PhD, Pathologist. *Room 1* [Adv, AYA, Ped, PF]


213 Medullary thyroid cancer roundtable: Including MEN2 and familial MTC. Bill McClain and Kathryn Wall, ThyCa Volunteers. *Room 3* [M]

214 Racial disparities in thyroid cancer.
Debbie Chen, MD, Endocrinologist. *Room 4*

215 Anaplastic thyroid cancer roundtable: Discussion with a doctor.
Jochen J. Lorch, MD, MSc, Medical Oncologist. *Room 5* [A]

11:30 – 11:40 a.m. EDT

221 Welcome and announcements. Anita Hubbard, ThyCa Volunteer. *Room 1*

11:45 a.m. – 12:45 p.m. EDT

231 Biomarker testing: Advanced cancer that needs testing to look for NTRK, RET and other therapeutic targets. Naífa L. Busaidy, MD, Endocrinologist. *Room 1* [Adv, PF]

232 The ABCs of thyroid cancer: Explaining key terms, concepts, and initial diagnostic and treatment steps. Angela M. Leung, MD, Endocrinologist. *Room 2*

233 Panel discussion: Updates from the MTC & MEN2 registry.
Ruth A. Amaku, MPH, Senior Research Coordinator, Jessica Foft, Clinical Research Coordinator, Jessica E. Gosnell, MD, Endocrine Surgeon, Elizabeth G. Grubbs, MD, Surgeon, Mimi I. Hu, MD, Endocrinologist, Maya Lodish, MD, MHS, Endocrinologist, Susan K. Peterson, PhD, MPH, Behavioral Scientist, and Julie Ann Sosa, MD, MA, Surgeon. *Room 3* [M]

234 Panel discussion: Pediatric thyroid cancer session 1. *Room 4* [Ped]
- Building a National Consortium to advance the care of pediatric patients with thyroid cancer. Andrew J. Bauer, MD, FAAP, Pediatric Endocrinologist, Aime T. Franco, PhD, Researcher, Amber R. Isaza, BA, Clinical Research Coordinator, and Ken Kazahaya, MD, MBA, FACS, Otolaryngologist.
- When should families worry about an inheritable risk for developing thyroid cancer.
  Jonathan Wasserman, PhD, Pediatric Endocrinologist

235 en español: Una mesa redonda entre nosotros. Damaris Fernández, Claudia Figueroa, Mayte Sánchez, MD, y Socorro Vélez. Habitación 5 [Esp]

Session Key by Suggested Audience

You are welcome to attend any session. The key indicates sessions of interest to a particular audience.

**A**: Anaplastic  **Adv**: Advanced Disease  **AYA**: Adolescent/Young Adult  **C**: Caregivers  **Esp**: Spanish  **M**: Medullary  **N**: Newly Diagnosed  **Ped**: Pediatric  **PF**: Papillary/Follicular
Saturday, October 24, 1:15 – 2:15 p.m. EDT

241 Controversies in the management of differentiated thyroid cancer/papillary thyroid cancer.
Julie Ann Sosa, MD, MA, Surgeon. Room 1 [N, PF]

242 Your mouth, salivary glands, and teeth: Preventing and solving issues caused by treatments including radioactive iodine or external beam radiation.
Mark S Chambers, DMD, MS, Oral Medicine Specialist. Room 2

243 Panel discussion: Locoregionally advanced, recurrent, and distant metastatic medullary thyroid cancer. Douglas W. Ball, MD, Endocrinologist, Ralph P. Tufano, MD, Otolaryngologist, and Mark E. Zafereo, MD, Head and Neck Surgeon. Room 3 [M]

244 Panel discussion: Pediatric thyroid cancer session 2. Room 4 [Ped]
- Surgical management of pediatric thyroid cancer; how to reduce complications. Ken Kazahaya, MD, MBA, FACS, Otolaryngologist.
- What are the lifetime risks associated with the use of RAI therapy during childhood and adolescence. Adina L. Alazraki, MD, Pediatric Radiologist.

245 Panel discusión quirúrgica. Habitación 5 [Esp]
- Seguimiento activo en cáncer bien diferenciado de tiroides, en lesiones pequeñas. Hernan Tala, MD, Endocrinólogo.
- Tratamiento quirúrgico del cáncer de tiroides. Carlos S. Duque, MD, Cirujano de Cabeza y Cuello.

2:45 – 3:45 p.m. EDT

251 Post-operative issues: Incidence, causes, prevention, and solutions.
David Myssiorek, MD, FACS, Otolaryngologist Room 1 [M,PF]

252 Reclaiming Your Sexual Self After Cancer.
Marloe Esch, RN, OCN, Oncology Nurse Room 2

253 Radioactive iodine (RAI) therapy for RAI-refractory disease: “redifferentiation”.
Steven I. Sherman, MD, Endocrinologist. Room 3

254 Panel discussion: Pediatric thyroid cancer session 3. Room 4 [Ped]
- Monitoring for and treating thyroid cancer in survivors of non-thyroid malignancies. Sogol Mostoufi-Moab, MD, MSCE, Pediatric Endocrinologist and Oncologist.
- Transitions: Helping young survivors understand and begin to manage their thyroid cancer. Catherine DINauer, MD, Pediatric Endocrinologist, and Aime T. Franco, PhD, AYA Survivor.

255 Panel de discusión: Tratamiento después de la cirugía. Habitación 5 [Esp]
- ¿Cuáles son las indicaciones del yodo radioactivo? Juan Antonio Vallejo, MD, Jefe de servicio de Medicina Nuclear
- ¿Cómo es el seguimiento del cáncer de tiroides luego de ser tratado? Jaydira Del Rivero, MD, Oncólogo, Endocrino.

**Session Key by Suggested Audience**

You are welcome to attend any session. The key indicates sessions of interest to a particular audience.

Saturday, October 24, 4:15 – 5:15 p.m. EDT

261 Targeted Therapies for Advanced Differentiated Thyroid Cancers; Patient Expectations.
Description: An overview of thyroid cancer care as it has evolved to today's new approved therapies, therapies in clinical trials and on the horizon as well as future therapies in development.
Andrew G. Gianoukakis, MD, Endocrinologist. Room 1 [A,ADV,M,PF]

262 How palliative care can be your 'pal' after a cancer diagnosis.
Reanne Booker, NP, MN, BSN, Nurse Practitioner. Room 2

263 A Patients Progress on Curing MTC with Cell Therapy: CAR-T and TCR-Transduced T cells That Recognize and Lyse MTC Cells.
Timothy Erickson, PhD, Patient Researcher. Room 3 [M]

264 Panel discussion: Pediatric thyroid cancer session 4. Room 4 [Ped]
- Differences in clinical behavior and genetics between pediatric and adult patients with papillary thyroid cancer. Aime T. Franco, PhD, Researcher.
- When should systemic therapy be considered for pediatric patients with thyroid cancer. Steven G. Waguespack, MD, Adult and Pediatric Oncologic Endocrinologist.

265 Panel de discusión: Haga sus preguntas a los médicos. Jaydira Del Rivero, MD, Oncólogo Endocrino, Carlos S. Duque, MD, Cirujano de Cabeza y Cuello, Hernan Tala, MD, Endocrinologo, y Juan Antonio Vallejo, MD, Jefe de servicio de Medicina Nuclear, o. Habitación 5 [Esp]

5:45 – 6:45 p.m. EDT

271 Roundtable: Radioactive iodine (RAI) resistant thyroid cancer. Elizabeth Holliday, ThyCa Volunteer. Room 1 [Adv]

272 Roundtable: Craft and Connect. Alexa Jett, ThyCa Volunteer. Room 2

273 Roundtable: Long-term survivors talk about their journeys. ThyCa Volunteer. Room 3

274 AYA Roundtable: Selfcare and thyroid cancer. Samantha Weese, ThyCa Volunteer. Room 4 [AYA]

275 Roundtable: Anaplastic thyroid cancer. Cheri Lindle, MEd, ThyCa Volunteer. Room 5 [A]

Support the 19th ThyCa Auction
Go to www.thyca.org/auction and help us raise much needed funds for thyroid cancer research. The auction ends at 9 p.m. EDT tonight.

Session Key by Suggested Audience
You are welcome to attend any session. The key indicates sessions of interest to a particular audience.
Sunday, October 25, 2020

- Registration is open, go to [www.thyca.org/conference](http://www.thyca.org/conference)
- All program times are EDT
- Visit the Exhibit Hall
- Your feedback is important! Please fill out your evaluation forms

10:00 – 11:10 a.m. EDT

301 A quick look into the impact of COVID-19 on thyroid cancer care. And, an overview into research into outcomes. Carrie C. Lubitz, MD, MPH, Surgeon. *Room 1*

302 Approaches for RAI therapy and RAI refractory (RAI resistant) disease. Mabel Ryder, MD, Endocrinologist. *Room 2*

303 Medullary thyroid cancer roundtable: Questions as we begin day 3. Karen Geisenberger, ThyCa Volunteer. *Room 3 [M]*

304 ThyCa support group facilitators: current and prospective. Kathryn Wall, Director of Support Groups, and Theresa Wickerham, ThyCa Program Coordinator. *Room 4*


11:30 – 11:40 a.m. EDT

311 Welcome and announcements. Howard Solomon, ThyCa Volunteer. *Room 1*

11:45 a.m. – 12:45 p.m. EDT

321 Panel discussion: Treatment options to learn about as we pursue care for papillary and follicular thyroid cancer. Moderator: R. Michael Tuttle, MD, Endocrinologist. *Room 1 [PF]*

- Active surveillance as a treatment option. Megan R. Haymart, MD, Endocrinologist.

- Percutaneous alcohol ablation of nodules. Mabel Ryder, MD, Endocrinologist.

- The role of Radio Frequency Ablation, and other thermal ablation techniques, in the management of thyroid cancer. Jennifer H. Kuo, MD, MS, Endocrine Surgeon.

322 Before radioactive iodine. (1) Imaging and how it impacts radioactive iodine dose selection. (2) Determining dose selection when not using dosimetry. Erik Mittra, M.D., Ph.D., Nuclear Medicine Physician. *Room 2 [ADV,PF]*

323 Medullary thyroid cancer: Update on medical management, including discussing RET inhibitors. Bryan McIver, MD, ChB, PhD, Endocrinologist. *Room 3*

324 Low-Iodine diet roundtable discussion. Daria Jerauld, BE, MS, ThyCa Volunteer. *Room 4*

---

**Session Key by Suggested Audience**

You are welcome to attend any session. The key indicates sessions of interest to a particular audience.

A: Anaplastic  Adv: Advanced Disease  AYA: Adolescent/Young Adult  C: Caregivers  Esp: Spanish

M: Medullary  N: Newly Diagnosed  Ped: Pediatric  PF: Papillary/Follicular
Sunday, October 25, 1:15 – 2:15 p.m. EDT

331 Panel discussion: A patient-focused tumor board. What goes on "behind the scenes" when physicians discuss cases in a multidisciplinary session. Angela M. Leung, MD, Endocrinologist, Masha J. Livhits, MD, Endocrine Surgeon, and Michael W. Yeh, MD, Endocrine Surgeon. Room 1

332 Panel discussion: Is there a difference in how we are treated at different radiology facilities? What about between medical centers and community offices? Crispin A. Chinn, MD, Nuclear Medicine Physician, and Erik Mittra, M.D., Ph.D., Nuclear Medicine Physician Room 2 [ADV,PF]

333 Thyroid cancer: Everything I want to know in a discussion with a medical oncologist and a survivor but have been afraid to ask. George Labonte, MTC Survivor, and Lori J. Wirth, MD, Medical Oncologist. Room 3 [ADV,M,PF]

334 An attempt to help families understand communication FUNK; both with each other as well as with their medical team. Differences are confusing and can be a catalyst to strong emotions. We will examine the necessity of emotional intelligence, and look at behavioral styles through the lens of DiSC. “We don’t see things as they are, we see them as we are.” (Anais Nin). Cheri Lindle, MEd. Room 4

2:45 – 3:45 p.m. EDT

341 Panel discussion: Final question and answer session. We will address whatever questions have come up as the meeting has progressed. Moderator: R. Michael Tuttle, MD, Endocrinologist. Panelists: Avital Harari, MD, MSc, Endocrine Surgeon, Mabel Ryder, MD, Endocrinologist, and Lori J. Wirth, MD, Medical Oncologist. Room 1

3:50 – 4:00 p.m. EDT

351 Conference wrap-up: Resources and next steps after the conference, your feedback on the conference, and suggestions for next year. Gary Bloom, ThyCa Executive Director, Theresa Wickerham, ThyCa Program Coordinator, and Conference Team. Room 1

Thank you for coming! We hope to see you next year in Los Angeles, California!

Session Key by Suggested Audience
You are welcome to attend any session. The key indicates sessions of interest to a particular audience.
A: Anaplastic   Adv: Advanced Disease   AYA: Adolescent/Young Adult   C: Caregivers   Esp: Spanish
M: Medullary   N: Newly Diagnosed   Ped: Pediatric   PF: Papillary/Follicular